Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/42097
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChanitra Thuwajiten_US
dc.contributor.authorPeti Thuwajiten_US
dc.contributor.authorPranisa Jamjantraen_US
dc.contributor.authorChawalit Pairojkulen_US
dc.contributor.authorSopit Wongkhamen_US
dc.contributor.authorVajarabhongsa Bhudhisawasdien_US
dc.contributor.authorJunya Onoen_US
dc.contributor.authorShoichiro Ohtaen_US
dc.contributor.authorKiminori Fujimotoen_US
dc.contributor.authorKenji Izuharaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherShino-Test Corporationen_US
dc.contributor.otherSaga Medical Schoolen_US
dc.contributor.otherKurume University School of Medicineen_US
dc.date.accessioned2018-12-21T07:00:49Z
dc.date.accessioned2019-03-14T08:03:07Z-
dc.date.available2018-12-21T07:00:49Z
dc.date.available2019-03-14T08:03:07Z-
dc.date.issued2017-01-01en_US
dc.identifier.citationOncology Letters. Vol.14, No.1 (2017), 623-634en_US
dc.identifier.issn17921082en_US
dc.identifier.issn17921074en_US
dc.identifier.other2-s2.0-85020186876en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020186876&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/42097-
dc.description.abstract© 2017, Spandidos Publications. All rights reserved. An effective serum biomarker may improve cholangiocarcinoma (CCA) management. Periostin (PN) has been demonstrated to be associated with aggressive CCA. The current study evaluated PN in blood serum for its diagnostic and prognostic potential in patients with CCA. Sera of 68 patients with CCA were collected prior to treatment, and PN levels were measured using an ELISA. Sera from 50 normal controls, 6 patients with benign liver diseases, 2 with hepatocellular carcinoma and 21 with breast cancer were analyzed. Immunohistochemistry of PN in CCA tissues was also investigated. The data were analyzed using the Mann-Whitney U test, Kaplan-Meier log rank tests, Cox proportional hazard regression models and Fisher's exact tests. The median serum PN level in patients with CCA was significantly increased compared with that in healthy controls, patients with benign liver diseases and patients with breast cancer (all P<0.05). Using an optimal threshold value of 94 ng/ml PN, the diagnostic values for CCA compared with other conditions demonstrated a sensitivity level of 0.38 [95% confidence interval (CI), 0.27-0.51], specificity of 0.90 (95% CI, 0.81-0.96), accuracy of 0.66 (95% CI, 0.58-0.74), positive predictive value of 0.76 (95% CI, 0.59-0.89) and negative predictive value of 0.63 (95% CI, 0.53-0.72) (P<0.001). Furthermore, PN stain in stromal fibroblasts in CCA tissues was associated with serum PN levels (P=0.001), and patients with CCA were classified as low (≤94 ng/ml) or high PN (>94 ng/ml) accordingly. High serum and tissue PN levels were significantly associated with reduced survival rate (P<0.001 and P=0.033, respectively). Serum PN was an independent prognostic factor with a hazard ratio of 3.197 (P=0.001). In conclusion, serum PN may be used to divide patients with intrahepatic CCA into high and low PN groups. Elevated serum PN may be utilized as a marker of poor prognosis in patients with CCA.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020186876&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleClustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosisen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.3892/ol.2017.6250en_US
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.